Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Perez on the Adjuvant Treatment of Breast Cancer

January 28th 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, reviews clinical trials that are investigating the optimal adjuvant treatment for patients with breast cancer.

Addition of PI3K Inhibitor May Prevent or Delay Resistance to Therapy in HER2+ Breast Cancer

January 23rd 2013

A new study found that patients with HER2-positive breast cancer who are receiving anti-HER2 therapy could prevent or delay resistance when a phosphatidylinositol-3 kinase (PI3K) inhibitor is added during treatment.

The Future of BRCA1/BRCA2 Testing

January 22nd 2013

A pair of studies could change the way patients are evaluated for mutations of BRCA1 and BRCA2, two cancer susceptibility genes closely associated with breast and ovarian cancers, as well as other tumor types.

Dr. Gradishar Reviews Findings From the LEA Trial

January 17th 2013

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, reviews results from the phase III LEA trial that investigated add-on bevacizumab in breast cancer.

Dr. Sara Tolaney on Cabozantinib in Breast Cancer

January 16th 2013

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute and Brigham and Women's Hospital, discusses trials investigating cabozantinib in breast cancer.

Dr. Schuster on Detecting Bone Metastases in Breast Cancer

January 15th 2013

David Schuster, MD, director, from Emory University, compares the efficacy of bone scans and FDG-PET/CT scans for detecting bone metastases in patients with breast cancer.

Dr. Debu Tripathy on the CDK4/6 Inhibitor PD 0332991

January 11th 2013

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined the CDK inhibitor PD 0332991 for women with advanced estrogen receptor-positive breast cancer.

Dr. Perez on the Phase III Eribulin/Capecitabine Study

January 9th 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, discusses the results of a phase III study comparing the efficacy of eribulin mesylate to capecitabine in patients with locally advanced or metastatic breast cancer.

Dual Pathways Must Be Targeted in ER-Positive Breast Cancer

January 4th 2013

Treating estrogen receptorâ€“positive breast cancer without sparking resistance is a complex endeavor that should involve simultaneously targeting the hormone-signaling and PI3 kinase molecular pathways

Dr. Gradishar Discusses 10 Years of Adjuvant Tamoxifen

January 4th 2013

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, discusses results from the international ATLAS study that was presented at the 2012 San Antonio Breast Cancer Symposium.

Should Analysis of Circulating Tumor Cells Be Part of Metastatic Breast Cancer Management?

December 22nd 2012

Circulating tumor cell counts can provide a variety of useful information for clinicians treating patients with metastatic breast cancer.

Cardiac Risks Higher in Older Women Receiving Adjuvant Trastuzumab

December 21st 2012

A retrospective study of older women with early-stage breast cancer who received adjuvant trastuzumab alone or in combination with anthracyclines has revealed a higher incidence of heart failure and cardiomyopathy.

Gaining Ground: Personal Losses Help Drive Pioneer in Stem Cell Study

December 12th 2012

An interview with Jenny C. Chang, MB BChir, MD, who broke new ground in cancer research when she identified and patented a 493-gene signature for breast cancer.

Dr. Arteaga on Key Takeaway Points From the 2012 SABCS

December 10th 2012

Carlos L. Arteaga, MD, from Vanderbilt-Ingram Cancer Center, describes key takeaway points for practicing oncologists, clinical investigators, and scientists from the 2012 SABCS.

Cognitive Impairment Previously Linked to Chemotherapy May Originate Before Treatment

December 8th 2012

The mental toll and stress of a breast cancer diagnosis might factor into the cognitive impairment experienced during chemotherapy treatment, commonly referred to as "chemo brain."

Dr. Twelves Compares Eribulin and Capecitabine

December 8th 2012

Christopher Twelves, MD, discusses results from a phase III trial that compared capecitabine to eribulin mesylate in women with metastatic breast cancer.

Justin Balko on the Diversity of Genetic Alterations in TNBC

December 8th 2012

Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, discusses research into clinically targetable genetic alterations in patients with triple-negative breast cancer.

Long-Term Follow-Up Supports Use of Hypofractionated Radiotherapy in Early-Stage Breast Cancer

December 7th 2012

Long-term follow-up results showed that the hypofractionated regimens were as effective as the 50-Gy standard in women with early-stage breast cancer.

Long-Term Data Confirms One-Year of Adjuvant Trastuzumab as Standard of Care

December 7th 2012

Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.

Dr. Yarnold on Hypofractionation in the START Trials

December 7th 2012

John Yarnold, MBBS, from The Institute of Cancer Research in London, discusses results from the START trials that examined hypofractionated radioatherapy for women with early breast cancer.